Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives $13.60 Consensus Price Target from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.60.

Several research analysts recently weighed in on OBIO shares. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research note on Thursday, May 14th. B. Riley Financial reduced their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Barclays lifted their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th.

Insider Activity at Orchestra BioMed

In related news, Director Eric S. Fain purchased 20,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $4.13 per share, with a total value of $82,600.00. Following the completion of the purchase, the director owned 91,709 shares in the company, valued at $378,758.17. This represents a 27.89% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Darren Sherman sold 15,000 shares of Orchestra BioMed stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $3.87, for a total transaction of $58,050.00. Following the completion of the transaction, the insider directly owned 1,184,327 shares in the company, valued at approximately $4,583,345.49. The trade was a 1.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders bought 49,636 shares of company stock worth $200,981. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OBIO. Alyeska Investment Group L.P. bought a new position in Orchestra BioMed in the third quarter valued at approximately $3,386,000. Pathstone Holdings LLC bought a new position in Orchestra BioMed in the third quarter valued at approximately $2,495,000. Vanguard Group Inc. lifted its stake in Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares in the last quarter. Simplify Asset Management Inc. bought a new position in Orchestra BioMed in the first quarter valued at approximately $932,000. Finally, 683 Capital Management LLC bought a new position in Orchestra BioMed in the fourth quarter valued at approximately $847,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Stock Up 3.4%

Shares of NASDAQ:OBIO opened at $3.99 on Tuesday. The company has a 50 day moving average of $4.13 and a 200-day moving average of $4.27. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The stock has a market cap of $238.92 million, a price-to-earnings ratio of -4.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. On average, sell-side analysts forecast that Orchestra BioMed will post -1.47 earnings per share for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.